Key Takeaways
- Sales fell 21% on price, not volume: Volume held steady but selling prices dropped sharply, driven by a shift from a sellers' to a buyers' market and high-cost inventory, compressing EBITDA margins by 200 bps.
- Pakhajan greenfield is the growth story: The new facility, designed to more than double capacity, begins trial runs post-Diwali with production and revenue contribution starting in early FY25, targeting ₹500-600 crores in phase 1.
- US subsidiary signals a direct-to-end-user push: A new wholly owned subsidiary aims to bypass distributors for long-term business assurance and higher margins, capitalizing on "very good" US demand.
- Margin recovery is delayed, not derailed: Management pushed back on a Q3 return to normalized 38-40% gross margins, citing ongoing market challenges, but expects marginal improvement from the current 17% EBITDA in H2 FY24.
- What to watch next quarter: The pace of the Pakhajan trial run and customer audits, any stabilization in European demand, and whether the "spark in inquiries" converts to orders that refill the pipeline.
Pakhajan Greenfield: The Next Growth Engine
- Capacity doubling: The greenfield project is designed to more than double the company's total capacity, with phase 1 adding significant volume for both existing products and two entirely new products.
- Trial run imminent: Trial-1 is scheduled to begin post-Diwali, with production and initial revenue contribution expected to commence in early FY25 (Q1 FY25).
- Revenue target: Phase 1 is expected to generate revenue in the range of ₹500 crores to ₹600 crores, depending on selling prices, targeting roughly 10% of the addressable business.
- Ramp-up trajectory: Management expects a gradual ramp-up, covering around 50% utilization of phase 1 capacity in FY25, with the first quarter potentially reaching only 15% to 30% utilization due to customer approvals and audits.
- Margin uplift expected: The new facility is expected to deliver slightly higher EBITDA margins of around 20%, compared to the current 17-18% from the legacy Vapi operations.
- Product mix: The facility will produce two new products alongside capacity expansions of products currently manufactured at Vapi, which are more voluminous, bulk-volume categories compared to Vapi's niche, low-volume output.
- Customer pipeline: For the new products, management has identified interested customers, but they will only come on board once production actually starts.
Parag Jhaveri: "Yes. So, those are new products and we have identified a number of customers who is interested in this, but they all will come on board once we start the production."
Margin & Pricing Dynamics
- The 200 bps compression: The drop in EBITDA margin was driven by two factors: high-cost inventory (responsible for 30-35% of the drop) and the discounts required to hold business in a market that has shifted from a sellers' to a buyers' dynamic.
- Price-led sales decline: A 21% fall in sales value occurred despite steady volumes, as selling prices corrected sharply, particularly in consumer care products and some specialty categories, while lubricant additives and rubber chemicals saw only slight corrections.
- High-cost inventory largely digested: Management stated that the major high-cost inventory has been utilized, except for one or two products still being carried, and the situation is largely normalized as of the reporting date.
- Mix improvement masked by pricing: Despite a favorable shift in product mix toward the higher-margin industrial segment, gross margins fell due to the dual impact of high-cost inventory and further margin reduction in consumer care.
- H2 recovery modest: Management cannot assure a return to a 19% EBITDA margin in H2 FY24 but expects to improvise marginally from the current 17%, with a more meaningful recovery pushed out to Q4 and beyond.
Parag Jhaveri: "In FY'22 and FY'23, there was more of sellers' market now it's become buyers' market. So, to hold on the business we have to give some discount. What we lost is about a 2%."
Demand & Geographic Outlook
- US demand "very good": Demand across all segments in the United States is robust, prompting the company to incorporate a new subsidiary to reach end users directly and capture higher margins.
- Europe remains a challenge: The European market is still under a question mark due to the ongoing geopolitical situation and a broader economic slowdown, which has pulled exports down from 69% to 62% of total sales year-on-year.
- Pipeline refilling: Despite the European slowdown, management noted a "spark in inquiries and orders for delivery in 2024," suggesting the pipeline is beginning to refill as customer inventories empty.
- Market diversification: To compensate for European weakness, the company has expanded its footprint into Asian, Middle Eastern, and Latin American markets.
- Market growth and share cap: The underlying market is growing at 3% to 5% from a demand perspective, but management has a self-imposed cap of 20% to 25% market share to avoid attracting larger competitors.
Parag Jhaveri: "While in USA the demand is you can use the word very good for all the segment... But Europe is there to challenge."
Segment & Product Dynamics
- Lubricant additives shine: The lubricant segment's contribution has improved substantially, with the company capturing more market share and adding new customers, while pricing in this category held relatively firm.
- Consumer care hit hardest: Volume was impacted in consumer care and one or two specialty products, with these categories also bearing the brunt of the price correction and margin compression.
- Vapi peak revenue defined: Management expects peak revenue from the legacy Vapi operations to be in the range of ₹700 crores to ₹750 crores, based on its 12,500 metric ton capacity.
- Normalized margin target: In a normalized year, management hopes to return to 38% to 40% gross margins and an EBITDA of about 18% to 19% from the Vapi operations, though no timeline is committed.
- Competitive intensity stable: Competition has not increased; rather, existing competitors are pricing lower due to reduced demand in certain categories, which has forced the company to offer discounts to hold business.
Balance Sheet & Strategy
- Debt peak and repayment: Peak debt is anticipated to exceed 500 crores, with repayment scheduled to begin in FY26. Per an analyst's math, only 7% of the new 270 crore debt will be repaid in the near term, though management did not confirm a specific quantum.
- US subsidiary strategy: The new wholly owned subsidiary in the United States is a strategic move to reach more end users directly, bypassing distributors to secure long-term business assurance and achieve higher margins.
- Market share discipline: Management explicitly stated a preference to stay below a 20% to 25% market share ceiling to avoid triggering competitive retaliation from much larger players.
Parag Jhaveri: "I would never like to cross more than 20%, 25% market share. That saying that one should be much happier with that. Otherwise, there are a lot of big players who can come and hurt you badly."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Pakhajan trial run | Trial-1 to commence | Post-Diwali (Q3 FY24) |
| Pakhajan production start | Production and revenue contribution to begin | Early FY25 (Q1 FY25) |
| Pakhajan phase 1 utilization | Cover around 50% utilization | FY25 |
| Pakhajan phase 1 revenue | ₹500 crores to ₹600 crores | Phase 1 (no end date specified) |
| Vapi peak revenue | ₹700 crores to ₹750 crores from 12,500 MT capacity | At peak utilization |
| Vapi normalized margins | 38-40% gross margin, 18-19% EBITDA | In a normalized year (no timeline) |
| H2 FY24 margin improvement | Improvise marginally from current 17% EBITDA | H2 FY24 |
| Debt repayment start | Repayment of peak debt (>500 crores) to begin | FY26 |
| FY24 utilization | Achieve at least 90% utilization | FY24 |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Revenue (H1 FY24) | Sales value decreased 21% due to a fall in selling price |
| Exports share | 62% of total sales, declined from 69% YoY |
| Consumer chemicals revenue share | ~70% of revenue |
| Industrial chemicals revenue share | ~83% of total revenue |
| Gross margin | 33% to 34%, dropped from 38% to 40% previously |
| EBITDA margin | 17%, dropped by about 2 percentage points YoY |
| EBITDA margin drop attribution | 30% to 35% of the 200 bps drop due to high-cost inventory |
| Vapi capacity utilization | ~85% |
| Total capacity | 12,500 metric tons after debottlenecking |
| Vapi peak revenue potential | ₹700 cr to ₹750 cr at 12,500 metric ton capacity |
| Pakhajan phase 1 revenue expectation (FY25) | ₹500 cr to ₹600 cr, targeting 50% utilization in FY25 |
| Pakhajan expected EBITDA margin | 20% if all goes well |
| Product D sales | ~₹35 cr |
| Net debt | ₹475 cr, increased from ₹275-300 cr; peak debt anticipated over ₹500 cr |
| Market growth rate | 3% to 5% demand growth |